Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine - PubMed (original) (raw)
. 2008 Jun;33(7):1690-703.
doi: 10.1038/sj.npp.1301547. Epub 2007 Sep 5.
Affiliations
- PMID: 17805312
- DOI: 10.1038/sj.npp.1301547
Differential effects of antipsychotic and glutamatergic agents on the phMRI response to phencyclidine
Alessandro Gozzi et al. Neuropsychopharmacology. 2008 Jun.
Abstract
Acute administration of NMDA receptor (NMDAR) antagonists such as phencyclidine (PCP) or ketamine induces symptoms that closely resemble those of schizophrenia in humans, a finding that has led to the hypothesis that a decreased NMDAR function may be a predisposing or even causative factor in schizophrenia. However, the precise neuropharmacological mechanisms underlying these effects remain to be fully elucidated. Here, we applied pharmacological MRI (phMRI) to examine the brain circuitry underlying the psychotomimetic action of PCP in the anesthetized rat, and investigated how these functional changes are modulated by drugs that possess distinct pharmacological mechanisms. Acute administration of PCP (0.5 mg/kg i.v.) produced robust and sustained positive relative cerebral blood volume (rCBV) changes in discrete cortico-limbo-thalamic regions. Pretreatment with the selective D2 dopamine antagonist raclopride (0.3 mg/kg i.p.) did not significantly affect the rCBV response to PCP, while the atypical antipsychotic clozapine (5 mg/kg i.p.) produced region-dependent effects, with complete suppression of the rCBV response in the thalamus, and weaker attenuation of the response in cortical and hippocampal structures. The response to PCP was strongly suppressed in all regions by pretreatment with two drugs that can inhibit aberrant glutamatergic activity: the anticonvulsant lamotrigine (10 mg/kg i.p.) and the mGluR2/3 agonist LY354740 (10 mg/kg i.p.). Taken together, our findings corroborate the pivotal role of dysfunctional glutamatergic neurotransmission in the functional response elicited by PCP, while the lack of effect of raclopride argues against a primary role of dopamine D2 receptor activation in this process. Finally, the thalamic effect of clozapine could be key to elucidating the functional basis of its pharmacological action.
Similar articles
- Drug-anaesthetic interaction in phMRI: the case of the psychotomimetic agent phencyclidine.
Gozzi A, Schwarz A, Crestan V, Bifone A. Gozzi A, et al. Magn Reson Imaging. 2008 Sep;26(7):999-1006. doi: 10.1016/j.mri.2008.01.012. Epub 2008 May 16. Magn Reson Imaging. 2008. PMID: 18486387 - Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.
Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O'Daly OG, Williams SC, Mehta MA. Doyle OM, et al. J Pharmacol Exp Ther. 2013 Apr;345(1):151-60. doi: 10.1124/jpet.112.201665. Epub 2013 Jan 31. J Pharmacol Exp Ther. 2013. PMID: 23370794 Clinical Trial. - Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
Javitt DC. Javitt DC. Int Rev Neurobiol. 2007;78:69-108. doi: 10.1016/S0074-7742(06)78003-5. Int Rev Neurobiol. 2007. PMID: 17349858 Review. - [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L. Mechri A, et al. Encephale. 2001 Jan-Feb;27(1):53-9. Encephale. 2001. PMID: 11294039 Review. French.
Cited by
- Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat.
Gozzi A, Herdon H, Schwarz A, Bertani S, Crestan V, Turrini G, Bifone A. Gozzi A, et al. Psychopharmacology (Berl). 2008 Dec;201(2):273-84. doi: 10.1007/s00213-008-1271-z. Epub 2008 Aug 15. Psychopharmacology (Berl). 2008. PMID: 18704372 - Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain.
Jenkins BG. Jenkins BG. Neuroimage. 2012 Aug 15;62(2):1072-85. doi: 10.1016/j.neuroimage.2012.03.075. Epub 2012 Apr 1. Neuroimage. 2012. PMID: 22495143 Free PMC article. Review. - The Role of fMRI in Drug Development: An Update.
Carmichael O. Carmichael O. Adv Neurobiol. 2023;30:299-333. doi: 10.1007/978-3-031-21054-9_13. Adv Neurobiol. 2023. PMID: 36928856 - Sertindole restores attentional performance and suppresses glutamate release induced by the NMDA receptor antagonist CPP.
Carli M, Calcagno E, Mainini E, Arnt J, Invernizzi RW. Carli M, et al. Psychopharmacology (Berl). 2011 Apr;214(3):625-37. doi: 10.1007/s00213-010-2066-6. Epub 2010 Nov 4. Psychopharmacology (Berl). 2011. PMID: 21049266 - Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.
Barnes SA, Sawiak SJ, Caprioli D, Jupp B, Buonincontri G, Mar AC, Harte MK, Fletcher PC, Robbins TW, Neill JC, Dalley JW. Barnes SA, et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(2):pyu010. doi: 10.1093/ijnp/pyu010. Int J Neuropsychopharmacol. 2014. PMID: 25552430 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical